Business Description
Myriad Genetics Inc
NAICS : 325413
SIC : 2835
ISIN : US62855J1043
Share Class Description:
MYGN: Ordinary SharesDescription
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.7 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -2.75 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.18 | |||||
| Beneish M-Score | -2.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.9 | |||||
| 3-Year EBITDA Growth Rate | -8 | |||||
| 3-Year EPS without NRI Growth Rate | -12.2 | |||||
| 3-Year Book Growth Rate | -10.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.27 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.73 | |||||
| 9-Day RSI | 42.78 | |||||
| 14-Day RSI | 35.67 | |||||
| 6-1 Month Momentum % | -19.51 | |||||
| 12-1 Month Momentum % | -6.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | |||||
| Quick Ratio | 1.73 | |||||
| Cash Ratio | 0.65 | |||||
| Days Inventory | 35.62 | |||||
| Days Sales Outstanding | 52.39 | |||||
| Days Payable | 44.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.4 | |||||
| Shareholder Yield % | 2.14 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.15 | |||||
| Operating Margin % | -12.26 | |||||
| Net Margin % | -14.09 | |||||
| FCF Margin % | -13.03 | |||||
| ROE % | -15.68 | |||||
| ROA % | -10.41 | |||||
| ROIC % | -11 | |||||
| ROC (Joel Greenblatt) % | -50.44 | |||||
| ROCE % | -11.94 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 132.4 | |||||
| PE Ratio without NRI | 118.21 | |||||
| PS Ratio | 1.78 | |||||
| PB Ratio | 2.06 | |||||
| Price-to-Tangible-Book | 11.34 | |||||
| EV-to-EBIT | -13.4 | |||||
| EV-to-Forward-EBIT | -16.35 | |||||
| EV-to-EBITDA | -29.22 | |||||
| EV-to-Forward-EBITDA | -31.88 | |||||
| EV-to-Revenue | 1.85 | |||||
| EV-to-Forward-Revenue | 2.25 | |||||
| EV-to-FCF | -14.17 | |||||
| Price-to-Projected-FCF | 18.46 | |||||
| Price-to-Median-PS-Value | 0.65 | |||||
| Price-to-Graham-Number | 7.76 | |||||
| Earnings Yield (Greenblatt) % | -7.46 | |||||
| FCF Yield % | -7.12 | |||||
| Forward Rate of Return (Yacktman) % | -8.11 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MYGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Myriad Genetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 823.6 | ||
| EPS (TTM) ($) | -1.3 | ||
| Beta | 2.03 | ||
| Volatility % | 44.5 | ||
| 14-Day RSI | 35.67 | ||
| 14-Day ATR ($) | 0.783297 | ||
| 20-Day SMA ($) | 16.13 | ||
| 12-1 Month Momentum % | -6.45 | ||
| 52-Week Range ($) | 14.72 - 29.3 | ||
| Shares Outstanding (Mil) | 91.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Myriad Genetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Myriad Genetics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Myriad Genetics Inc Frequently Asked Questions
What is Myriad Genetics Inc(MYGN)'s stock price today?
The current price of MYGN is $16.55. The 52 week high of MYGN is $29.30 and 52 week low is $14.72.
When is next earnings date of Myriad Genetics Inc(MYGN)?
The next earnings date of Myriad Genetics Inc(MYGN) is 2025-02-27 Est..
Does Myriad Genetics Inc(MYGN) pay dividends? If so, how much?
Myriad Genetics Inc(MYGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers